Irampanel

DB21123InvestigationalSmall molecule

Irampanel is a small molecule drug. Irampanel is under investigation in clinical trial NCT02222961 (Single Increasing Dose Followed by Maintenance Dose Tolerance Study of BIIR 561 CL in Healthy Male... Irampanel has a monoisotopic molecular weight of 309.15 Da.

Mechanism: Pharmacologically active on Voltage-gated sodium channel alpha subunit
Curator reviewed
Formula / weight: C₁₈H₁₉N₃O₂ · 309.369 g/mol (avg)
Code names: BIIR-561 · BIIR-561 CL

Resolves to

Compound

UNIIR2GZD7LMYXCAS206260-33-5ChEMBLCHEMBL29741

Structure

InChIKeyQZULPCPLWGCGSL-UHFFFAOYSA-NSMILESCN(C)CCOC1=C(C=CC=C1)C1=NC(=NO1)C1=CC=CC=C1

What you can answer from here — as of September 16, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which companies are running trials of Irampanel, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account